RESUMO
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway, cross-talk with estrogen receptors, immune response, cell cycle control mechanisms, and other tyrosine kinase receptors such as insulin-like growth factor I receptor are potential pathways involved in trastuzumab resistance. Different therapeutic interventions targeting these pathways are currently under evaluation.
RESUMO
El congreso más importante a nivel mundial sobre cáncer es el de la American Society of Clinical Oncology, que tiene carácter anual y en el que se presentan las novedades más relevantes en los diferentes campos de la Oncología. Respecto al cáncer de mama, la principal novedad ha sido en la primera línea de tratamiento en pacientes HER2 con la llegada del pertuzumab. A continuación, resumimos lo más destacado que se ha presentado en relación con el cáncer de mama(AU)
The most important world congress on cancer is the Annual Meeting of the American Society of Clinical Oncology (ASCO), where the most notable findings in the distinct fields of oncology are presented. This year, the main novelty in breast cancer was related to the first line treatment of metastatic HER2 disease with the development of pertuzumab. This article summarizes the innovations presented in the field of breast carcinoma(AU)